Document:

Material Transfer and Research License Agreement

 Exhibit 10.8 
  
 CONFIDENTIAL 
  
 MATERIAL TRANSFER, AND LIMITED RESEARCH LICENSE AND 
 EXCLUSIVITY PERIOD, AGREEMENT 
 (DRAFT 1.0) 
  
 THIS MATERIAL TRANSFER, AND LIMITED RESEARCH LICENSE AND EXCLUSIVITY PERIOD, AGREEMENT (the
“Agreement”) dated as of July 6, 2005 (the “Effective Date”), is entered into between AEGIS THERAPEUTICS, INC., a California corporation (“PROVIDER”), having a place of business at 10919 Technology
Place, Suite C, San Diego, CA 92127, and Phage Biotechnology Corporation, Inc., a Delaware corporation (the “RECIPIENT”), having a place of business at 101 Theory, Suite 200, Irvine, CA 92617. The parties agree as follows:

  
 Definitions: 
  
 Designated Recipient’s Scientist: (please designate): John Guastella,
Ph.D. 
  
 Original Material: IntravailTM delivery
enhancement agents - alkylsaccharide surfactants and formulations thereof as described in US Patent No. 5,661,130. 
  
 MATERIAL: Original Material plus Modifications and Unmodified Derivatives whether produced by PROVIDER or RECIPEINT. 
  
 Unmodified Derivatives: substances or formulations created by RECIPIENT which
constitute an unmodified form or functional sub-unit the Original Material, for example but not by way of limitation, formulations at concentrations not specifically disclosed in US Patent No. 5,661,130 or mixtures of different alkylglycosides.

  
 Modifications: substances or formulations created by RECIPIENT which
contain/incorporate alkylglycosides having chemical compositions or concentrations that may differ from those disclosed in US Patent No. 5,661,130 or which may be used individually or in combination, or in combination with other materials not
specified in US Patent No. 5,661,130. 
  
 Terms and Conditions of this
Agreement 
  

	1.	The MATERIAL is the property of PROVIDER and is to be used by RECIPIENT, at RECIPIENT’s company (or institution) only, and only under the direction of the Recipient’s
Scientist. The RECIPIENT shall use the MATERIAL, and any information and other materials directly or indirectly derived therefrom, solely to conduct the noncommercial research described in the workplan attached hereto as Exhibit A, and they shall
not be used for any other purpose whatsoever. The MATERIAL will not be used in human subjects or in clinical trials involving human subjects without the written permission of PROVIDER. The Recipient shall not (and shall not attempt or purport to)
file or prosecute in any country any patent application which claims or uses or purports to claim or use the MATERIAL, or any information or other materials directly or indirectly derived therefrom, without the prior express written consent of
PROVIDER. 

  

 1 

 CONFIDENTIAL 
  

	2.	The Recipient’s Scientist agrees not to transfer the MATERIAL to anyone who does not work under his or her direct supervision at RECIPIENT’s company without the prior
written consent of PROVIDER. Recipient’s Scientist shall refer any request for the MATERIAL to PROVIDER. 

  

	3.	Only upon express written permission from PROVIDER, may RECIPIENT distribute the MATERIAL for commercial or research use. It is recognized by RECIPIENT that such commercial or
research use may require a license from PROVIDER and PROVIDER has no obligation to grant such a license. 

  

	4.	Except as may be expressly provided in this Agreement, no rights are provided to RECIPIENT under any patents, patent applications, trade secrets or other proprietary rights of
PROVIDER. In particular, no rights are provided to use the MATERIAL and any related patents or intellectual property of any kind of PROVIDER for profitmaking, commercial or research purposes, including but not limited to sale of the MATERIAL, use in
manufacturing, provision of a service to a third party in exchange for consideration, or use in research or consulting by a commercial or not for-profit entity under which that entity obtains rights of any sort to research results.

  

	 	a.	If RECIPIENT desires to use the MATERIAL or Modifications for such commercial purposes, RECIPIENT agrees, in advance of such use, to negotiate in good faith with PROVIDER to
establish the terms of an appropriate license. It is understood by RECIPIENT that PROVIDER shall have no obligation to grant such a license to RECIPIENT, and may grant exclusive or non-exclusive licenses to others. 

  

	 	b.	If the research involving the MATERIAL results in an invention or a Modification, regardless of whether may be commercially useful, Recipient’s Scientist agrees to promptly
disclose the invention or Modification to RECIPIENT and PROVIDER. Inventorship for such invention shall be deemed to be that of PROVIDER. RECIPIENT, in cooperation with Recipient’s Scientist, shall promptly supply PROVIDER with a copy of the
disclosure (and/or a sample of the Modification) for PROVIDER’s evaluation purposes. PROVIDER shall have the sole right to determine what, if any, patent applications should be filed. PROVIDER also retains full ownership of the MATERIALS as
defined above and sole licensing rights. 

  

	5.	The provision of the MATERIAL to RECIPIENT shall not alter any preexisting right to the MATERIAL. 

  

	6.	Any MATERIAL delivered pursuant to this Agreement is understood to be experimental in nature and may have hazardous properties. PROVIDER MAKES NO REPRESENTATIONS AND EXTENDS NO
WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER
PROPRIETARY RIGHTS. 

  

 2 

 CONFIDENTIAL 
  

	7.	RECIPIENT assumes all liability for damages that may arise from its use, storage or disposal of the MATERIAL. PROVIDER will not be liable to RECIPIENT for any less, claim or demand
made by RECIPIENT, or made against RECIPIENT by any other party, due to or arising from the use of the MATERIAL by RECIPIENT, except to the extent caused by the gross negligence or willful misconduct of PROVIDER. 

  

	8.	This Agreement shall prohibit publication of the existence of this Agreement and of any research resulting from the use of the MATERIAL. If PROVIDER gives its express written
consent to such publication and the text of such publication, RECIPIENT agrees to provide appropriate acknowledgment of the source of the MATERIAL in all publications and a reasonable number of copies of any such publications.

  

	9.	RECIPIENT agrees to provide PROVIDER with a copy of all test results within 14 days of completion of the study. PROVIDER may use such results for any lawful business purpose except
that PROVIDER may not disclose identity of RECIPIENT without its express written consent. 

  

	10.	RECIPIENT agrees to use the MATERIAL in compliance with all applicable statutes and regulations including, for example, those relating to research involving the use of animals.

  

	11.	This Agreement will terminate on the earliest of the following dates: (1) on completion of RECIPIENT’s current research with the MATERIAL, or (2) on thirty
(30) days written notice by either party to the other, or (3) on the following date (insert date). Paragraphs 7, 8, 9 and 10 shall survive termination. 

  

	 	a.	Except as provided in 12 (c) below, on termination of this Agreement under 12 (1), (2) or (3), above, RECIPIENT will discontinue its use of the MATERIAL as defined in this
transfer agreement and will, upon direction of PROVIDER, return or destroy any remaining MATERIAL. 

  

	 	b.	In the event PROVIDER terminates this Agreement under 12 (2) above other than for breach of this Agreement or with cause such as an imminent health risk or patent infringement,
PROVIDER will defer the effective date of termination for a period of up to 15 days (or insert reasonable time for completion), upon request from RECIPIENT, to permit completion of research in progress. 

 

	12.	In return for the fee specified in Attachment A, PROVIDER grants RECIPIENT: (1) a research license to conduct all studies as described herein and to use the results for
purposes of evaluating its interest in licensing PROVIDER’s technology relating to the use of MATERIAL for human therapeutic applications, and (2) a 60 day period of guaranteed exclusivity to negotiate a license, under usual and generally
accepted industry terms, for the application of the PROVIDER’s technology relating to the use of MATERIAL, for application to intranasal formulations for administering E. coli derived human growth hormone, for human therapeutic purposes.

  

 3 

 CONFIDENTIAL 
  

	13.	This Agreement shall not be construed to grant any license or other rights to the RECIPIENT in any patent rights or other intellectual property rights of PROVIDER except as
specifically set forth in this AGREEMENT. 

  

	14.	The RECIPIENT may not assign or otherwise transfer this Agreement, whether by voluntarily, by operation of law or otherwise, without the prior express written consent of PROVIDER.
Any purported assignment or transfer of this Agreement in violation of this section shall be void. 

  

	15.	This Agreement represents the entire agreement between the parties regarding the subject matter hereof and shall supersede all previous communications, representations,
understandings and agreements, whether oral or written, by or between the parties with respect to the subject matter hereof. 

  

	16.	No change, modification, extension, termination or waiver of this Agreement, or any of the provisions herein contained, shall be valid unless made in writing and signed by duly
authorized representatives of the parties. 

  

	17.	The RECIPIENT’s use and evaluation of the Materials shall be at its own risk. The RECIPIENT shall hold harmless and indemnify PROVIDER against any and all losses, liabilities,
damages and expenses (including reasonable attorneys’ fees and costs) of every kind arising from the use and evaluation by the RECIPIENT of the Materials. 

  

	18.	A breach of any of the promises or agreements contained herein will result in irreparable and continuing damage to PROVIDER for which there will be no adequate remedy at law, and
PROVIDER shall be entitled to injunctive relief and/or a decree for specific performance, and such other relief as may be proper (including monetary damages if appropriate). 

  

	19.	This Agreement shall be governed by and construed in accordance with the laws of the State of California, U.S.A., without regard to the conflicts of law principles thereof.

  
 {The remainder of this page has been
intentionally left blank} 
  

 4 

 CONFIDENTIAL 
  

	20.	IN WITNESS WHEREOF, the parties have entered into this Agreement as of the Effective Date. 

  

											
	AGREED:	 	 	 	 
			
	PROVIDER	 	 	 	 
				
	 	 	 Aegis Therapeutics, LLC
 16870 West Bernardo
Drive, Suite 390
 San Diego, CA 92127
	 	 	 	 
				
	 	 	 Authorized Official: Edward T. Maggio, Ph.D.
	 	 	 	 

											
	 	 	 Title: Chief Executive Officer
	 	 	 	 

											
					
	 	 	Signature:	 	 	 	 	 	Date:
                                       
 

  

											
	RECIPIENT	 	 	 	 
				
	 	 	 Phage Biotechnology Corporation, Inc.
 101
Theory, Suite 200,
 Irvine, CA 92617
	 	 	 	 
				
	 	 	 Authorized Official: Jack Jacobs, Ph. D.
	 	 	 	 

											
	 	 	 Title: COO and CSO
	 	 	 	 

											
					
	 	 	Signature:	 	 	 	 	 	Date:
                                       
 

  

											
	 Recipient’s Scientist
	 	 	 	 
				
	 	 	 Name: John Guastella, Ph.D.
	 	 	 	 

											
	 	 	 Title: Sr. Director, Scientific Operations
	 	 	 	 

											
					
	 	 	Signature:	 	 	 	 	 	Date:
                                       
 

  

 5 

 CONFIDENTIAL 
  
 Exhibit A – The Workplan 
  
 The MATERIAL will be used solely for the testing of one or more IntravailTM delivery enhancement agents in the following tests: See Attached MPI Study

  
 Research License and Exclusivity Period Fee: None

  

 6Participatory Interests Purchase Agreement

 Exhibit 10.9 
  
 PARTICIPATORY INTERESTS PURCHASE AGREEMENT 
  
 This Participatory Interest Purchase Agreement (this “Agreement”) is made as of September 30, 2005
(the “Effective Date”) by and among Phage Biotech Ukraine, LLC (“PBU”), a Nevada limited liability company, and Cardio Phage International (“CPI”), a Bahamas corporation (collectively the “Sellers”), and BS
Biology Sciences Limited, a Cyprus corporation (the “Buyer”). 
  
 In consideration of the mutual agreements set forth below, the receipt and sufficiency of which is hereby acknowledged, the Sellers and Buyer agree as follows: 
  
 1. Sale/Purchase of the Participatory Interests. The Sellers hereby sells, transfers and delivers to Buyer, and Buyer
hereby purchases, all of the currently owned by the Sellers and outstanding participatory interests (the “Interests”) of Phage Biotech, a Ukrainian limited liability company (the “Company”), which total par value is the Hryvnya
equivalent of six hundred eighty six thousand five hundred thirty five US Dollars and sixty one cent (US$686,535.61), subject to the following terms and conditions of this Agreement. Of the Interests, PBU owns 99% and CPI owns 1%. 

 
 2. Purchase Price. In consideration of the sale, transfer,
assignment, conveyance and delivery by the Sellers of the Interests to Buyer, Buyer shall pay to the Sellers, in readily available funds, the amount of one hundred three thousand four hundred ninety US Dollars (US$103,490.00) (the “Purchase
Price”) to be divided pro-rata between the Sellers. Such amount may be adjusted based on asset values revised as of the Effective Date. If adjustments require any additional amount from Buyer, Buyer shall promptly remit such amount to Sellers
as set forth below. If adjustments require any refund to Buyer, Sellers shall promptly refund such amount to Buyer. 
  
 3. Representations and Warranties of the Sellers. Each of the Sellers individually represents and warrants to Buyer that: 
  
 3.1 Organization and Authority. The Company is a
limited liability company duly organized and validly existing under the laws of Ukraine and has full authority and power to carry on its business as now conducted. 
  
 3.2 Authorization: Binding Obligations. This Agreement has been duly authorized, executed and
delivered by each of the Sellers. This Agreement, when duly executed and delivered by each of the Sellers and the Buyer, will be a valid and binding obligation of each of the Sellers, enforceable against each of them in accordance with its terms,
subject only to bankruptcy, insolvency, moratorium or similar proceedings affecting the rights of creditors generally, and general principles of equity. 
  
 3.3 Title to Company Assets. The Company has good title to, or a valid leasehold interest in, all assets reflected in the Company
financial statements on the Effective Date, a sample balance sheet of which is attached hereto. as Exhibit A. 

 3.4 Capitalization. 
  
 (a) The authorized capital of the Company consists of participatory interests, 99% of which is assigned to
PBU and 1 % of which is assigned to CPJ. The Sellers and Buyer hereby acknowledge that, as of the Effective Date, the total amount of such authorized capital is Nine Hundred Forty Thousand Three Hundred Fifty Two U.S. dollars and Nineteen Cents
($US 940,352.19). The Sellers and Buyer further acknowledge that the total amount of the contributions to such authorized capital (charter fund) of the Company as made by the Sellers shall be Six Hundred Eighty Six Thousand Five Hundred Thirty Five
U.S. dollars and Sixty One Cents ($US 686,535.61), which as of the Effective Date constitutes 73.01% of the authorized capital of the Company. The Sellers undertakes and the Buyer each individually and collectively agree to use commercially
reasonable efforts to execute any and all documents which may be required to effect the reduction of the authorized capital (charter fund) of the Company from $U5940,352.19 to $US686,535.61 and to file such documents with the appropriate Ukrainian
authorities, with the intent that as a result of the reduction of the authorized capital (charter fund) the Buyer shall acquire 100% thereof. 
  
 (b) There are no existing, outstanding or authorized options, warrants, purchase rights, subscription rights, conversion rights, exchange
rights, or other contracts or commitments that could require the Company to issue, sell, or otherwise cause to become outstanding any of its participatory interests or any other participatory interest of the Company. There are no outstanding or
authorized appreciation rights, phantom stock, profit participation or similar rights of any character relating to the Company. 
  
 4. Representations and Warranties of Buyer. Buyer represents and warrants to the Sellers that: 
  
 4.1 Organization and Authority. Buyer is duly
organized and validly existing under the laws of Cyprus and has full power and authority to carry on its business as now conducted. 
  
 4.2 Authorization: Binding Obligations. This Agreement has been duly authorized, executed and delivered by Buyer. This Agreement,
when duly executed and delivered by Buyer and the Sellers will be valid and binding obligation of Buyer, enforceable against it in accordance with its terms, subject only to bankruptcy, insolvency, moratorium or similar proceedings affecting the
rights of creditors generally, and general principles of equity. 
  
 5. Deliveries. On the Effective Date or as soon as practical thereafter, the following transactions shall take place: 
  
 5.1 Documents to be Delivered by Sellers. The Sellers deliver the following to the Buyer: 
  
 (a) Notice of Waiver of First Refusal Rights; 
  
 (b) Notarized minutes of the meeting of the
Participants’ Assembly of the Company, whereby the sale of the Interest is authorized; and 

 (c) All such other bills of sale, assignments and other instruments of assignment,
transfer or conveyance as Buyer may reasonably request or as may be otherwise necessary to evidence and effect the sale, transfer, assignment, conveyance and delivery of the Interests to Buyer and to put Buyer in actual possession or control of the
Interests and the business of the Company. 
  
 5.2 Documents to be Delivered by Buyer. Buyer shall deliver the following to the Sellers: 
  
 (a) Proof of payment by wire transfer of US$102,455.10 to the bank account to be designated by PBU; and 
  
 (b) Proof of payment by wire transfer of US$1,034.90 to the
bank account to be designated by CPI. 
  
 6. The title to the
Interests shall pass from the Sellers to the Buyer on the Effective Date as set forth above (the “Title Transfer Date”). The Parties hereto affirm, that on or about the Effective Date all participants of the Company and the Company itself
received Notice of Waiver of First Refusal Rights with respect to purchase of the CPI’ s Interest signed by PBU; and that on or about the Effective Date all participants of the Company and the Company itself received Notice of Waiver of First
Refusal Rights with respect to purchase of the PBU’s Interests signed by CPI. Consequently, the Effective Date shall be the Title Transfer Date. 
  
 7. From the Title Transfer Date, the Buyer shall acquire all of the rights and assume all of the obligations associated with the participation in the
Company to the extent of the Interests acquired by it, and CPI and PBU from the Title Transfer Date shall be relieved from any of such rights and obligations associated with the Interests transferred hereunder. 
  
 8. Post-Effective Obligations. The Sellers and Buyer each individually
and collectively agree to use commercially reasonable efforts to execute and file any and all required documents with the Ukrainian government to effectuate the reduction of the amount of the authorized capital (charter fund) of the Company and to
effectuate the sale of the Interests hereunder. The Sellers and Buyer further agree to diligently carry out any additional act required, and to cooperate with each other as necessary, to carry out the intent and purpose of this Agreement. The
Sellers and Buyer acknowledge that the dollar amounts above may require adjustment depending on the timing of the filing of certain documents with the appropriate government authorities and the parties agree to any fair and equitable adjustment, if
required. 
  
 9. Disclaimer and Condition of Company
Assets. It is understood and acknowledged by the parties hereto that, subject to Section 3.3 hereof, the Company assets are on an “as is, where is” basis and the Sellers disclaim all warranties with respect to the Company assets,
including any implied warranties of merchantability and fitness for any particular purpose. In no event shall the Sellers be liable for indirect, incidental, consequential or exemplary damages, including without limitation, damages for loss of
profits, or other tangible and intangible losses resulting from use, quality, design, merchantability or functioning of the Company assets after the Effective Date, or damages for illness or injury to any person resulting from use of the Company
assets after the Effective Date. 

 10. Confidentiality. After the Effective Date, each party shall hold all information with respect
to the terms and conditions of this Agreement in confidence and shall not, directly or indirectly, use such information for its own benefit or disclose the same to any third party without the other party’s written consent. 
  
 10.1 Either the Sellers or the Buyer may disclose
information, which would otherwise be confidential, if and to the extent: 
  
 (a) such disclosure is required by the applicable Ukrainian legislation; 
  
 (b) the information is in its possession, or is in the public domain, through no fault of either the Sellers or the Buyer; or 

 
 (c) such disclosure is to either the Sellers’ or the
Buyer’s legal advisors, accountants or other consultants, who are also subject to the same or similar confidentiality restrictions as are contained in this Article 10. 
  
 11. Applicable Law. This Agreement shall in all respects be governed by and construed in accordance with the laws of
California, United States of America, without giving effect to the principles of conflict of laws. 
  
 12. Dispute Resolution. All disputes, which arise out of or in connection with this Agreement, or its interpretation, operation, or termination,
shall, in the first instance, be settled by means of amicable negotiations between the Sellers and the Buyer. In the event that any such dispute between the Sellers and the Buyer can not be resolved by means of such negotiations, either party
thereto undertake to transfer such dispute to binding arbitration with California, United States of America as the venue using the rules of the American Arbitration Association. 
  
 13. Miscellaneous. 
  
 (a) The performance of any act or payment by one party shall not be deemed a waiver of any obligation or default on the part of the other.
One party’s failure to require strict performance by the other party of any of the provisions of this Agreement shall not be a waiver thereof. 
  
 (b) This Agreement constitutes the entire understanding between the parties and supersedes any previous representations or agreements,
whether verbal or written, with respect to the sale of the Interests. 
  
 (c) No amendment or change of any of the terms or conditions herein shall be binding upon the parties unless they are made in writing and are signed by an authorized representative of each party. 
  
 (d) Any provision of this Agreement which is unenforceable
shall not cause any other remaining provision to be ineffective or invalid. The captions set forth herein are for convenience only and shall not define or limit any of the terms hereof. Any notices or demands in connection with this Agreement shall
be given in writing by certified mail at the address indicated in this Agreement, or to any other address specified in writing. 

 (e) None of the parties shall be liable or deemed to be in default for any delay or
failure in performance under this Agreement or interruption of service resulting directly or indirectly from acts of God or military authority, acts of public enemy, war, riots, civil disturbances, insurrections, accidents, fire, explosions,
earthquakes, floods, the elements, strikes, labor disputes, shortages of the equipment or components thereof suitable parts, materials, labor or transportation, or any other causes beyond the reasonable control of such party. 
  
 (f) This Agreement may be executed in one or more
counterparts, and via facsimile, each of which, including an identical photo, chemical or electronic copy, shall be deemed an original but all of which shall constitute one and the same instrument. 
  
 IN WITNESS WHEREOF, the parties signing below each have the authority to sign
and enter into this Agreement and have executed this Agreement as of the Effective Date. 
  

			
	 THE SELLERS

	
	 Phage Biotech Ukraine,
 a Nevada limited liability company

		
	By	 	/S/    MICKAEL A.
FLAA        
	 Name:
	 	Mickael A. Flaa
	 Title:
	 	Manager
	
	 Cardio Phage International,
 a Bahamas corporation

		
	By	 	/S/    GRANT
GORDON        
	 Name:
	 	Grant Gordon
	 Title:
	 	President
	
	 BUYER

	
	 BS Biology Sciences Limited,
 a Cyprus company

		
	By	 	/S/    PETROS
LIVANIOS        
	 Name:
	 	Petros Livanios
	 Title:
	 	Director

  
 EXHIBIT A 
  
 Balance Sheet of Phage Biotech on March 31, 20005 
  

							
	 Purchase Price (noted below, highlighted, bold with *** around it):
	  	***103.49***

  
 Amounts are in US Dollars 

 

									
	 Assets

	  	Code

	  	For the
beginning of
accounting
period
(31 Dec 2004)

	 	 	For the end of
accounting
period
(31 March 2005)

	 
	 1. Capital assets
	  	 	  	 	 	 	 	 
	 Intangible assets:
	  	 	  	 	 	 	 	 
	 depreciated book value
	  	010	  	0.15	 	 	0.11	 
	 cost value (initial)
	  	011	  	0.17	 	 	0.17	 
	 depreciation
	  	012	  	(0.02	)	 	(0.06	)
	 Uncompleted construction
	  	020	  	—  	 	 	—  	 
	 Basic means:
	  	 	  	 	 	 	 	 
	 depreciated book value
	  	030	  	91.03	 	 	80.1	 
	 cost value (initial)
	  	031	  	182.47	 	 	176.64	 
	 amortization
	  	032	  	(91.44	)	 	(96.54	)
	 Long-term financial investments:
	  	 	  	 	 	 	 	 
	 share in other enterprises’ capital
	  	040	  	—  	 	 	—  	 
	 other financial investments
	  	045	  	—  	 	 	—  	 
	 long-term accounts receivable
	  	050	  	—  	 	 	—  	 
	 deferred tax assets
	  	060	  	—  	 	 	—  	 
	 Goodwill
	  	065	  	—  	 	 	—  	 
	 Other capital assets
	  	070	  	—  	 	 	—  	 
	 	  	
	  	
	
	 	
	

	 Total for section 1
	  	080	  	91.18	 	 	80.21	 
	 	  	
	  	
	
	 	
	

	 2. Current assets
	  	 	  	 	 	 	 	 
	 Inventories and supplies:
	  	 	  	 	 	 	 	 
	 production supplies
	  	100	  	7.82	 	 	12.52	 
	 animals tested
	  	110	  	—  	 	 	—  	 
	 uncompleted construction
	  	120	  	—  	 	 	—  	 
	 end products
	  	130	  	—  	 	 	—  	 
	 goods
	  	140	  	—  	 	 	—  	 
	 Notes
	  	150	  	—  	 	 	—  	 
	 Accounts receivable for goods, services:
	  	 	  	 	 	 	 	 
	 net realizable value
	  	160	  	—  	 	 	—  	 
	 cost value (initial)
	  	161	  	—  	 	 	—  	 
	 doubtful debts
	  	162	  	—  	 	 	—  	 
	 Accounts receivable due to budget
	  	170	  	0.04	 	 	0.15	 
	 for advanced payments
	  	180	  	3.37	 	 	4.32	 
	 from accrued income
	  	190	  	—  	 	 	—  	 
	 from internal settlements
	  	200	  	—  	 	 	—  	 
	 Other current accounts receivable
	  	210	  	0.72	 	 	0.51	 
	 Current financial investments
	  	220	  	—  	 	 	—  	 
	 Cash or equivalent:
	  	 	  	 	 	 	 	 
	 national currency
	  	230	  	2.71	 	 	9.2	 
	 foreign currency
	  	240	  	12.06	 	 	4.0	 
	 Other current assets
	  	250	  	—  	 	 	—  	 
	 	  	
	  	
	
	 	
	

	 Total for section 2
	  	260	  	26.72	 	 	30.70	 
	 	  	
	  	
	
	 	
	

	 3. Future expenses
	  	270	  	—  	 	 	—  	 
	 	  	
	  	
	
	 	
	

	 Balance
	  	280	  	117.9	 	 	110.91	 
	 	  	
	  	
	
	 	
	

									
	 Liabilities

	  	Code

	  	For the
beginning of
accounting
period

	 	 	For the end of
accounting
period

	 
	 1. Equity capital
	  	 	  	 	 	 	 	 
	 Statutory fund
	  	300	  	554.37	 	 	554.37	 
	 Share capital
	  	310	  	—  	 	 	—  	 
	 Additional invested capital
	  	320	  	—  	 	 	—  	 
	 Other additional capital
	  	330	  	—  	 	 	—  	 
	 Reserve capital
	  	340	  	—  	 	 	—  	 
	 Undistributed profit (uncovered loss)
	  	350	  	(414.98	)	 	(450.88	)
	 Unpaid capital
	  	360	  	(22.19	)	 	—  	 
	 Withdrawn capital
	  	370	  	—  	 	 	—  	 
	 	  	
	  	
	
	 	
	

	 Total for section 1
	  	380	  	117.20	 	 	***103.49***	 
	 	  	
	  	
	
	 	
	

	 2. Costs and payments
	  	 	  	 	 	 	 	 
	 Salaries
	  	400	  	—  	 	 	—  	 
	 Other payments
	  	410	  	—  	 	 	—  	 
	 	  	415	  	—  	 	 	—  	 
	 	  	416	  	—  	 	 	—  	 
	 Target financing
	  	420	  	—  	 	 	—  	 
	 	  	
	  	
	
	 	
	

	 Total for section 2
	  	430	  	—  	 	 	—  	 
	 	  	
	  	
	
	 	
	

	 3. Long-term liability
	  	 	  	 	 	 	 	 
	 Long-term loans
	  	440	  	—  	 	 	—  	 
	 Other long-term financial liability
	  	450	  	—  	 	 	—  	 
	 deferred tax liability
	  	460	  	—  	 	 	—  	 
	 Other long-term liability
	  	470	  	—  	 	 	—  	 
	 	  	
	  	
	
	 	
	

	 Total for section 3
	  	480	  	—  	 	 	—  	 
	 	  	
	  	
	
	 	
	

	 4. Current liability
	  	 	  	 	 	 	 	 
	 Short-term loans
	  	500	  	—  	 	 	—  	 
	 Current receivables from long-term liability
	  	510	  	—  	 	 	—  	 
	 Notes
	  	520	  	—  	 	 	—  	 
	 Accounts receivable for goods, services
	  	530	  	0.40	 	 	0.41	 
	 Current receivables:
	  	 	  	 	 	 	 	 
	 from received advanced payments
	  	540	  	0.30	 	 	0.28	 
	 due to budget
	  	550	  	—  	 	 	0.59	 
	 from non-budget payments
	  	560	  	—  	 	 	—  	 
	 Pension & social fund
	  	570	  	—  	 	 	2.01	 
	 from salaries
	  	580	  	—  	 	 	4.13	 
	 before members
	  	590	  	—  	 	 	—  	 
	 from internal calculations
	  	600	  	—  	 	 	—  	 
	 Other current liability
	  	610	  	—  	 	 	—  	 
	 	  	
	  	
	
	 	
	

	 Total for section 4
	  	620	  	0.70	 	 	7.42	 
	 	  	
	  	
	
	 	
	

	 5. Future income
	  	630	  	—  	 	 	—  	 
	 	  	
	  	
	
	 	
	

	 Balance
	  	640	  	117.9	 	 	110.91

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}]]